Dr. Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development. Surrozen forms a Clinical Advisory Board of leading retinal specialists. Data presentations at the Association for Research in Vision and Ophthalmology Annual Meeting and Clinical Trials Summit. Surrozen announces financial results for the second quarter of 2025, focusing on its ophthalmology pipeline and developing novel treatments for severe eye diseases. Key events in the second quarter of 2025 include progress in the ophthalmology pipeline, patent issuance, and the appointment of Dr. Daniel Chao as Vice President and Head of Clinical Development. Surrozen’s Clinical Advisory Board formation and scientific presentations at ARVO and CTS highlight the company’s advancements in retinal disease treatment. Financial highlights for the second quarter of 2025 show a cash position of $90.4 million, research service revenue from a related party, and details of operating expenses. Surrozen’s ophthalmology portfolio includes SZN-8141 for retinal diseases, combining Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism. Surrozen is developing SZN-8141, which has shown promise in treating diabetic retinopathy, retinal vein occlusion, and wet AMD by stimulating Wnt signaling and promoting normal retinal vessel regrowth. SZN-8143 combines various agents to potentially benefit patients with DME, wet AMD, and uveitic macular edema. SZN-413, a bi-specific antibody, targets Fzd4-mediated Wnt signaling to treat retinal vascular-associated diseases effectively.
Surrozen’s innovative approach aims to selectively modulate the Wnt pathway to treat severe eye diseases like diabetic retinopathy. The company’s technologies focus on leveraging the body’s repair mechanisms for disease management. Forward-looking statements highlight Surrozen’s commitment to developing product candidates with the potential to address unmet needs in serious eye diseases through research, discovery, and development activities.
The press release contains forward-looking statements about Surrozen’s development plans, including clinical trials and potential benefits of product candidates. Risks and uncertainties, such as economic conditions and regulatory factors, may impact the company’s ability to fund research and development efforts. Surrozen emphasizes the unpredictability of actual events and cautions against relying solely on forward-looking statements for decision-making. 1. The Dow Jones Industrial Average dropped 300 points today, attributed to concerns over rising inflation rates and ongoing trade tensions with China.
2. The unemployment rate in the United States has fallen to 3.9%, the lowest level in 18 years, as the economy continues to show signs of strength.
3. A new study has found that 70% of Americans are concerned about the impact of climate change, with extreme weather events becoming more frequent.
4. The World Health Organization reports that cases of measles have surged by 300% globally in the first three months of 2019, with outbreaks occurring in countries with low vaccination rates.
5. Researchers have discovered a new species of dinosaur in Argentina, named Lavocatisaurus agrioensis, shedding light on the diversity of dinosaurs in the region during the Cretaceous period.
Read more at GlobeNewswire.: Surrozen Reports Second Quarter 2025 Financial Results and